Join Jack McDonnell, MD, a pediatric immunologist and assistant professor at Cleveland Clinic Lerner College of Medicine, and Elie Haddad, MD, PhD, a clinician-researcher in pediatric immunology, full professor at the University of Montreal, and head of the Immunology and Rheumatology department at CHU Sainte-Justine, as they explore the evolving world of immune deficiency and dysregulation.
Presented by the Primary Immune Deficiency Treatment Consortium (PIDTC), this podcast features conversations with leading experts, pioneering researchers, patients, and advocacy groups. Each episode uncovers cutting-edge research, clinical challenges, and personal stories—ensuring that the patient voice remains at the center of the discussion.
Whether you're a clinician, researcher, patient, or advocate, Immune Matters brings you the latest insights in diagnosis, treatment, and innovation in primary immune disorders.
Tune in to explore the science, the stories, and the future of immune health.
The Primary Immune Deficiency Treatment Consortium (PIDTC) is a part of the Rare Diseases Clinical Research Network of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH).
This work was supported by the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (DAIT, NIAID) and the ORDR under cooperative agreements U54-AI082973 and U54-NS064808 and grants R13-AI094943 and 1R24AI184316-01.
The content and opinions expressed are solely the responsibility of the authors and do not represent the official policy or position of the NIAID, ORDR, NCATS, NIH, HRSA, or any other agency of the US Government.
All content for Immune Matters: a PIDTC Podcast is the property of Jack McDonnell and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Join Jack McDonnell, MD, a pediatric immunologist and assistant professor at Cleveland Clinic Lerner College of Medicine, and Elie Haddad, MD, PhD, a clinician-researcher in pediatric immunology, full professor at the University of Montreal, and head of the Immunology and Rheumatology department at CHU Sainte-Justine, as they explore the evolving world of immune deficiency and dysregulation.
Presented by the Primary Immune Deficiency Treatment Consortium (PIDTC), this podcast features conversations with leading experts, pioneering researchers, patients, and advocacy groups. Each episode uncovers cutting-edge research, clinical challenges, and personal stories—ensuring that the patient voice remains at the center of the discussion.
Whether you're a clinician, researcher, patient, or advocate, Immune Matters brings you the latest insights in diagnosis, treatment, and innovation in primary immune disorders.
Tune in to explore the science, the stories, and the future of immune health.
The Primary Immune Deficiency Treatment Consortium (PIDTC) is a part of the Rare Diseases Clinical Research Network of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH).
This work was supported by the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (DAIT, NIAID) and the ORDR under cooperative agreements U54-AI082973 and U54-NS064808 and grants R13-AI094943 and 1R24AI184316-01.
The content and opinions expressed are solely the responsibility of the authors and do not represent the official policy or position of the NIAID, ORDR, NCATS, NIH, HRSA, or any other agency of the US Government.
In this episode of Immune Matters, Dr. Jack McDonnell and Dr. Elie Haddad welcome Dr. Jen Heimall, an expert in severe combined immune deficiency (SCID). They discuss the complexities of SCID, including its diagnosis, management, and the importance of newborn screening. Dr. Heimall shares insights from her research on treatment outcomes and the significance of collaboration in SCID care. The conversation also touches on the challenges faced by patients and families, the evolving landscape of gene therapy, and the urgent questions that remain in the field of immunology.
Keywords
SCID, immune deficiency, pediatric immunology, bone marrow transplant, gene therapy, patient experience, newborn screening, PIDTC, immunology research, immune system
Immune Matters: a PIDTC Podcast
Join Jack McDonnell, MD, a pediatric immunologist and assistant professor at Cleveland Clinic Lerner College of Medicine, and Elie Haddad, MD, PhD, a clinician-researcher in pediatric immunology, full professor at the University of Montreal, and head of the Immunology and Rheumatology department at CHU Sainte-Justine, as they explore the evolving world of immune deficiency and dysregulation.
Presented by the Primary Immune Deficiency Treatment Consortium (PIDTC), this podcast features conversations with leading experts, pioneering researchers, patients, and advocacy groups. Each episode uncovers cutting-edge research, clinical challenges, and personal stories—ensuring that the patient voice remains at the center of the discussion.
Whether you're a clinician, researcher, patient, or advocate, Immune Matters brings you the latest insights in diagnosis, treatment, and innovation in primary immune disorders.
Tune in to explore the science, the stories, and the future of immune health.
The Primary Immune Deficiency Treatment Consortium (PIDTC) is a part of the Rare Diseases Clinical Research Network of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH).
This work was supported by the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (DAIT, NIAID) and the ORDR under cooperative agreements U54-AI082973 and U54-NS064808 and grants R13-AI094943 and 1R24AI184316-01.
The content and opinions expressed are solely the responsibility of the authors and do not represent the official policy or position of the NIAID, ORDR, NCATS, NIH, HRSA, or any other agency of the US Government.
